These data demonstrate the ability of methylation-specific primers to detect DeMeth MOG-DNA in the blood of mice treated with the ODC-specific toxin, supporting the use of DeMeth MOG-DNA as a biomarker of ODC cell loss in MS. Here, MOG is linked to myeloid sarcoma.